Kidney Week

Abstract: PUB019

Prevalence of AKI in Patients Treated with Cisplatin

Session Information

• Publication Only

Category: Acute Kidney Injury

• 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

• Ortega, Jose Luis, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Jose Luis Ortega, MD

• Morales Lopez, Enrique Fleuvier, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Enrique Fleuvier Morales Lopez

• Alamilla-Sanchez, Mario, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Mario Alamilla-Sanchez, MD, MSc

• Rosillo-Salgado, Ydris Zelim, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Ydris Zelim Rosillo-Salgado, MD

• Torres Cuevas, Jose Luis, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Jose Luis Torres Cuevas, MD

• Gonzalez-Fuentes, Carolina, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Carolina Gonzalez-Fuentes, MD, MSc

• Ulloa Galvan, Victor Manuel, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Victor Manuel Ulloa Galvan, MD

• Yama Estrella, Martin Benjamin, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Martin Benjamin Yama Estrella, MD

• Salazar Hurtado, Jorge David, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Jorge David Salazar Hurtado, MD

• Rubio, Jesús Omar, Centro Medico Nacional 20 de Noviembre, Mexico City, Mexico City, Mexico

Jesús Omar Rubio, MD

Background

Cisplatin is a potent chemotherapy used in a wide spectrum of malignant tumors, however it has been associated to nephrotoxicity manifested by acute kidney injury and electrolyte disorders. The main objective of this study is to describe the frequency and the outcomes in patients with nephrotoxicity induced by cisplatin.

Methods

Retrospective cohort of 30 patients treated with cisplatin in a single Mexican third level healthcare center, data were collected from electronic clinical records. Descriptive analysis was performed with central tendency characteristics. Univariate logistic regression (odds ratios [OR], 95% CI) was used to evaluate renal outcomes and mortality

Results

Of the 30 participants, 21 (70%) were men, the more frequent comorbidity was arterial hypertension, 7 patients (23.3%) and only one patient had the diagnosis of chronic kidney disease. The median of glomerular filtration rate was 67 (55-77), 15 (50%) had acute kidney injury and 8 (26.7%) progressed to acute kidney disease, the mortality in the follow up was 10%. The more frequent electrolyte disorder was hypomagnesemia recorded in 16 (53.3%) of the participants, 14 (46.7%) was moderate (0.9-1.6 mg/dl), no severe hypomagnesemia (<0.9 mg/dl) was identified. Acute kidney injury was not associated to mortality but patients who had progression to acute kidney disease had a significant risk of mortality with a OR= 1.42, 95% CI, (1.11-1.81).

Conclusion

Nephrotoxicity induced by cisplatin is mainly manifested by acute kidney injury and hypomagnesemia, identified in 50% and 53.3% respectively. Patients with no recovery and progression to acute kidney disease had a significant risk to mortality, the limitation to aggressors of kidney function after nephrotoxicity induced by cisplatin could influence in the patient’s prognostic.